Sarepta Therapeutics, Inc.
Business Overview: Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Executive Summary
Sarepta Therapeutics is a Delaware-incorporated, commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics and gene therapy for rare neuromuscular diseases, with Duchenne muscular dystrophy (DMD) as its core franchise. The company markets four approved DMD therapies, including ELEVIDYS, the first approved gene therapy for DMD, and reported $1,864.3 million in net product revenue for 2025 (up from $1,788.0 million in 2024).
2025 was a turbulent year for Sarepta: ELEVIDYS shipments were suspended in July 2025 following safety concerns, resumed only for ambulatory patients on July 31, 2025, and a boxed warning for acute liver injury and acute liver failure was added in November 2025 — safety issues that have drawn heightened FDA scrutiny and led analysts to cut the company's gene-therapy revenue outlook into 2026.
1. Core Business Model & How They Work
[ RNA/Gene Therapy R&D (Internal + Arrowhead Partnership) ] ➡️ [ Orphan Drug / Accelerated Approval Pathways ] ➡️ [ Premium Pricing on Rare-Disease Therapies ] ➡️ [ Specialty Distribution to DMD Treatment Centers ] ➡️ [ Post-Market Safety Surveillance (Critical Given 2025 ELEVIDYS Events) ]2. Business Segments
Sarepta operates as a single segment focused on genetic medicines for rare neuromuscular and related diseases; products are organized by chemistry — PMO exon-skipping versus AAV gene therapy — rather than formal reporting segments.
3. Product Portfolio
| Product | Mechanism | Purpose | Why It Matters |
|---|---|---|---|
| EXONDYS 51 | PMO exon-51 skipping | DMD (exon 51 amenable), launched 2016 | First Sarepta DMD approval; established the exon-skipping franchise |
| VYONDYS 53 | PMO exon-53 skipping | DMD (exon 53 amenable), launched 2019 | Expands addressable DMD mutation population |
| AMONDYS 45 | PMO exon-45 skipping | DMD (exon 45 amenable), launched 2021 | Further expands addressable mutation population |
| ELEVIDYS | AAV gene therapy | DMD, launched 2023 | First approved DMD gene therapy; largest growth driver but center of 2025 safety crisis (liver injury boxed warning) |
4. Competitive Landscape
Item 1 does not name specific competitors or include a dedicated competition discussion in the portion reviewed. Independently, Sarepta's gene-therapy franchise faces indirect competitive and reputational pressure from the broader AAV gene-therapy field's safety track record, and its exon-skipping PMO franchise occupies a largely uncontested niche — few, if any, approved rivals address the same specific exon-skip mutations — though that also means each product's addressable patient population is inherently narrow.
5. Strategic Strengths & Risks
Strengths: a first-mover, largely uncontested position in DMD exon-skipping and in approved DMD gene therapy; orphan-drug/rare-disease regulatory pathways and deep DMD-specific clinical/commercial infrastructure are difficult for new entrants to replicate quickly; the Arrowhead partnership extends the pipeline into additional rare-disease indications (FSHD, DM1, ataxias, idiopathic pulmonary fibrosis, Huntington's) beyond DMD alone.
Risks: the November 2025 boxed warning for acute liver injury/failure on ELEVIDYS is a serious, company-specific safety event that already triggered a shipment suspension and reduced analyst revenue expectations; the company's core franchise is now under direct, heightened FDA scrutiny, with real risk of further label restrictions or enrollment limits; SRP-9003 (LGMD2E gene therapy) remains on FDA clinical hold, underscoring broader regulatory risk across Sarepta's gene-therapy pipeline beyond ELEVIDYS alone.
6. Financial Overview
| Metric | SRPT Profile | Context |
|---|---|---|
| FY2025 Net Product Revenue | $1,864.3M (vs. $1,788.0M FY2024) | Modest growth despite ELEVIDYS's mid-year shipment suspension |
| ELEVIDYS Status | Boxed warning added Nov. 2025; shipments resumed for ambulatory patients only (July 2025) | Material near-term overhang on the largest growth product |
| Pipeline | SRP-9003 (on clinical hold), SRP-1001/SRP-1003 (Arrowhead siRNA, Phase 1/2a) | Diversifying beyond DMD, but early-stage |
| Approved Products | 4 (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS) | Deep, DMD-specific commercial franchise |
7. Summary Conclusion
Sarepta built a genuine first-mover moat in Duchenne muscular dystrophy across both exon-skipping chemistry and gene therapy — but 2025's ELEVIDYS liver-safety crisis is a direct hit to the company's most important growth asset and its regulatory standing. The business's near-term trajectory depends heavily on whether ELEVIDYS's safety profile stabilizes under the new boxed warning and continued FDA scrutiny, or whether further restrictions erode the gene-therapy franchise that was meant to be Sarepta's next leg of growth.